Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.9610
+0.00190.20%
Pre-market: 0.96100.00000.00%04:08 EDT
Volume:251.05K
Turnover:237.38K
Market Cap:13.45M
PE:-0.09
High:0.9699
Open:0.9100
Low:0.9100
Close:0.9591
Loading ...

Company Profile

Company Name:
Moleculin Biotech
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
17
Office Location:
5300 Memorial Drive,Suite 950,Houston,Texas,United States
Zip Code:
77007
Fax:
- -
Introduction:
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Directors

Name
Position
Walter V. Klemp
Chairman of the Board, President and Chief Executive Officer
Elizabeth A. Cermak
Director
John M. Climaco
Director
Michael D. Cannon
Director
Robert E. George
Director

Shareholders

Name
Position
Walter V. Klemp
Chairman of the Board, President and Chief Executive Officer
Jonathan P. Foster
Chief Financial Officer and Executive Vice President
Donald Picker
Chief Scientific Officer
Robert Shepard
Chief Medical Officer - Annamycin
Sandra L. Silberman
Chief Medical Officer - New Products